Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
复制标题
DOI：
10.4088/jcp.08m04828
复制
发表时间：
2009-06
期刊：
影响因子：
--
通讯作者：
Weiner MF
中科院分区：
文献类型：
--
作者：
Siddique H;Hynan LS;Weiner MF
To ascertain the impact of treatment with citalopram on irritability, apathy, delusions and hallucinations in non-depressed behaviorally disturbed Alzheimer’s disease (AD) patients. This was a retrospective review of data from the 36-week CATIE trial in which AD patients were treated in a naturalistic manner with placebo, citalopram, risperidone, olanzapine or quetiapine, comparing scores on the Irritability, Apathy, Delusions and hallucinations subscales of the Neuropsychiatric Inventory. Of the 421 patients enrolled, 34 had been started on placebo and had been later randomized to citalopram treatment. There were data available for 34 subjects who had been on placebo for at least 14 days. In this group there was a 60% reduction in irritability and apathy scores, no effect on score for delusions, and a clinically insignificant drop in score for hallucinations. The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed AD patients.
